CRISPR Therapeutics AG
corporate_fare Company Profile
CRISPR Therapeutics AG (NASDAQ:CRSP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for CRSP at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- CRISPR Therapeutics Reports Widened Annual Loss, Increased CASGEVY Program Costs, and New Patent Litigation
- CRISPR Therapeutics Reports Q4 & FY25 Results, Highlights Strong CASGEVY Uptake & Pipeline Progress
- CRISPR Therapeutics Reports Positive Clinical Data for CTX310 and Autoimmune CAR-T Zugo-cel, Advances Pipeline
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$3.51M
Net Income
-$581.6M
Diluted EPS
-$6.47
Op. Cash Flow
-$345.01M
Free Cash Flow
-$345.93M
Operating Income
-$664.57M
Cash & Equivalents
$347.56M
Debt / Equity
0.00×
Net Margin
-165.70×
Shares Outstanding
95.89M sh
Source: 10-K · filed 2026-02-12 · accession 0001193125-26-048957
show_chartPrice Chart
Loading chart...
feed CRSP - Filings & News (Page 2)
CRSP
Feb 12, 2026, 4:59 PM EST
Price at Filing:
$49.95
Real-time Price:
$39.50
Change:
-$10.45 (-21%)
Market Cap:
$3.793B
CRSP
Feb 12, 2026, 4:35 PM EST
Price at Filing:
$49.79
Real-time Price:
$39.50
Change:
-$10.29 (-21%)
Market Cap:
$3.793B
CRSP
Jan 12, 2026, 8:44 AM EST
Price at Filing:
$54.30
Real-time Price:
$39.50
Change:
-$14.80 (-27%)
Market Cap:
$3.793B